JSJames Edward Self

James Edward Self

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


James Edward Self has a total of 514 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Genetic insights into foveal morphology and its associations with pigmentation and age-related macular degeneration

    by David J. Green, Thomas H. Julian, David Romero-Bascones, Sofia Torchia, Heer N. V. Joisher, Unai Ayala, Maitane Barrenechea, Jay E. Self, Graeme C. Black, Tomas Fitzgerald, et al.

    The fovea is the small depression at the neurosensory retina that underlies high-resolution central vision. It is vulnerable to disease and disruption of its architecture can lead to visual disability. Foveal morphology varies substantially across individuals but the molecular causes and functional consequences of this variation remain incompletely understood. Here, we analyse six foveal morphological parameters derived from optical coherence tomography (OCT) images of 39,521 UK Biobank participants. We find marked variation in foveal morphology and identify significant associations with sex and genetic ancestry. Genome-wide association studies identify 162 lead loci across the six foveal morphological parameters, implicating genes involved in pigmentation (including TYR , TSPAN10 and GPR143 ) and developmental patterning (including FGFR2 , CYP26C1 and CYP1A1 ). Heritability estimates range from 29 to 43%. Foveal pit volume is associated with future risk of age-related macular degeneration (AMD) (hazard ratio 1.09, p = 0.026), a finding supported by Mendelian randomisation. Given the strong correlations among foveal traits, the specificify of this association to pit volume remains unclear. These results establish foveal morphology as a highly heritable trait that is biologically linked to AMD.

  • Open Access

    Can a Portable Flash Visual Evoked Potential (VEP) Device Identify Chiasmal Decussation Anomalies in Albinism?

    by Eloise Keeling, Perry Carter, Abdi Malik Musa, Fatima Shawkat, Helena Lee, Jay E. Self

    Background: Visual evoked potentials (VEPs) are used to detect chiasmal misrouting associated with albinism. However, VEPs are only performed in specialist centres and typically have long waiting lists. The portable electrophysiology device RETeval® shows promise as a clinical screening tool across a range of ophthalmic conditions. Here, we explore its utility in detecting chiasmal abnormalities associated with albinism. Methods: Flash VEPs were recorded on the RETeval® and by standard ISCEV techniques for 27 patients with suspected albinism and 40 control patients as part of routine appointments. We retrospectively investigated the agreeability between the two methods. The amplitude/latency of the main component was measured for standard VEPs whilst a correlation value of interhemispheric difference was calculated for the RETeval® data. Results: We demonstrate a significant difference between albinism patients and controls (p < 0.001) with respect to the interhemispheric difference identified by the RETeval®. By applying a threshold of 0.001865 to the correlation value, the RETeval® detected chiasmal misrouting in all 27 patients with albinism and had 97% agreeability to standard testing. Conclusions: This study shows the potential of using the RETeval® as a clinical tool for the diagnosis of chiasmal anomalies in albinism. The RETeval® has significant time/cost savings which could hasten diagnoses.

  • Open Access

    Real-World Views of Patching Differ to Health Professionals’: An Online Survey of Professionals, Patients, Teachers, Parents and Carers

    by Daniel Osborne, Maddison McGowen, Jeremy Bradshaw, Helen Ellis, Megan Evans, James Stallwood, Joerg Fliege, Jay Self

    Background: Patching therapy is the most common treatment for amblyopia (lazy eye) and is unsuccessful for approximately 40% of patients, leaving them with life-long unilateral visual impairment and increased risk of bilateral visual impairment later in life. Poor adherence to patching therapy is a major contributing factor in treatment failure yet we lack real-world understanding as to why this is a problem outside of controlled research studies. Methods: In collaboration with patient contributors, we developed an online survey for past patients, parents/carers of children with amblyopia, health professionals, and schoolteachers. The survey included questions about when and where is best for children to wear the patch, the design of the patch, and facilitators and barriers to patching therapy. Results: We received 631 responses to the survey (259 health professionals, 213 parents/carers, 110 people who patched as a child, 7 teachers, and 42 people matched to multiple categories). Healthcare professionals thought weekday (54.4% versus 14.3% preferring weekend and 31.3% no difference) and school (54.4% versus 21.6% preferred home and 23.9% no difference) patching was more successful. Past patients (52.4%) favoured ‘force’ as a technique to encourage patching; more than both health professionals (7.7%) and parents or carers (19.7%). Patients rated ‘people making fun’ of them as an important barrier to patching. Conclusions: We describe surprising differences in stakeholders’ responses to the survey questions about barriers to successful patching treatment. We suggest these differences are used as a guide for further work to explore stakeholder’s social experience of patching.

  • Open Access

    Could a hand-held, visual electrophysiology device theoretically reduce diagnostic waiting times for complex eye conditions in the NHS? A Discrete Event Simulation (DES) modelling study

    by Steffen Bayer, Daniel Garillo, Marion Penn, Maria Chorozoglou, Sally Brailsford, Eloise Keeling, Fatima Shawkat, Perry Carter, Helena Lee, Jay E. Self

    Background/objectives: Visual Electro-Diagnostic Testing (EDTs) are a highly specialised service in the NHS. The high cost of tests and a paucity of trained visual electrophysiologists has resulted in very few services across the UK and, when combined with increasing patient backlogs, has caused significant travel burden and variable waiting times. Here, we study the potential for impact on patients and services by adding a screening step to traditional referral pathways using an Electroretinogram (ERG) test from a relatively inexpensive, portable, hand-held EDT device; the RETeval® (LKC technologies, Gaithersburg, MD, USA). Subjects/methods: We model a large regional-referral EDT service using Discrete Event Simulation (DES) modelling based on retrospective patient data and published best evidence for the device. We evaluate the potential impact that adding the screening step in referral pathways could have on patient waiting times should the device prove to be safe and useable in clinical practice. Results: We demonstrate that should the RETeval® ERG be safe and useable in real-world clinical practice, it has the potential to significantly reduce patient waiting times by avoiding lab-based EDT assessment for up to 45% of patients. We also show that the impact on services and patients is likely to be resilient to realistic changes in referral numbers, sensitivity/specificity of the device and changes in clinical capacity. Conclusions: This work demonstrates that a RETeval® ERG screening step, performed at the point of referral, has the potential to result in significantly reduced EDT waiting lists through fewer patients requiring lab-based EDT assessment and that DES modelling is a useful tool in making this assessment. However, many questions remain about using the device in the real-world setting for this purpose. Future studies are needed to assess its sensitivity/specificity, test/retest variability, changes in referral patterns due to the device, useability, acceptability to patients and importantly, the consequences of screening errors. Our work, using only retrospective data and a DES model, shows that using the device as an ERG screening tool warrants further investigation due to the potential impact on both patients and clinical services.


  • Open Access

    The UK clinical eye research strategy: refreshing research priorities for clinical eye research in the UK

    by Rupert R. A. Bourne, Malik Moledina, Augusto Azuara-Blanco, George M. Saleh, James E. Self, Sobha Sivaprasad, Srilakshmi M. Sharma, Andrew Ross, Rose M. Gilbert, Maram E. A. Abdalla Elsayed, et al.

    Objectives: To validate and update the 2013 James Lind Alliance (JLA) Sight Loss and Vision Priority Setting Partnership (PSP)’s research priorities for Ophthalmology, as part of the UK Clinical Eye Research Strategy. Methods: Twelve ophthalmology research themes were identified from the JLA report. They were allocated to five Clinical Study Groups of diverse stakeholders who reviewed the top 10 research priorities for each theme. Using an online survey (April 2021-February 2023), respondents were invited to complete one or more of nine subspecialty surveys. Respondents indicated which of the research questions they considered important and subsequently ranked them. Results: In total, 2240 people responded to the survey (mean age, 59.3 years), from across the UK. 68.1% were female. 68.2% were patients, 22.3% healthcare professionals or vision researchers, 7.1% carers, and 2.1% were charity support workers. Highest ranked questions by subspecialty: Cataract (prevention), Cornea (improving microbial keratitis treatment), Optometric (impact of integration of ophthalmic primary and secondary care via community optometric care pathways), Refractive (factors influencing development and/or progression of refractive error), Childhood onset (improving early detection of visual disorders), Glaucoma (effective and improved treatments), Neuro-ophthalmology (improvements in prevention, diagnosis and treatment of neurodegeneration affecting vision), Retina (improving prevention, diagnosis and treatment of dry age-related macular degeneration), Uveitis (effective treatments for ocular and orbital inflammatory diseases). Conclusions: A decade after the initial PSP, the results refocus the most important research questions for each subspecialty, and prime targeted research proposals within Ophthalmology, a chronically underfunded specialty given the substantial burden of disability caused by eye disease.


  • Measuring visual and quality of life outcomes in nystagmus; a scoping review protocol

    by Noah Clancy, Jane Vennik, Jay Self, Helena Lee

    INPLASY202450002 Measuring visual and quality of life outcomes in nystagmus; a scoping review protocol Keywords: Nystagmus; vision; visual function; quality of life; core outcome set. Download PDF …


  • Open Access

    Children’s visual acuity tests without professional supervision: a prospective repeated measures study

    by Daniel Osborne, Aimee Steele, Megan Evans, Helen Ellis, Roshni Pancholi, Tomos Harding, Jessica Dee, Rachel Leary, Jeremy Bradshaw, Elizabeth O’fLynn, et al.

    Background: Home visual acuity tests could ease pressure on ophthalmic services by facilitating remote review of patients. Home tests may have further utility in giving service users frequent updates of vision outcomes during therapy, identifying vision problems in an asymptomatic population, and engaging stakeholders in therapy. Methods: Children attending outpatient clinics had visual acuity measured 3 times at the same appointment: Once by a registered orthoptist per clinical protocols, once by an orthoptist using a tablet-based visual acuity test (iSight Test Pro, Kay Pictures), and once by an unsupervised parent/carer using the tablet-based test. Results: In total, 42 children were recruited to the study. The mean age was 5.6 years (range 3.3 to 9.3 years). Median and interquartile ranges (IQR) for clinical standard, orthoptic-led and parent/carer-led iSight Test Pro visual acuity measurements were 0.155 (0.18 IQR), 0.180 (0.26 IQR), and 0.300 (0.33 IQR) logMAR respectively. The iSight Test Pro in the hands of parents/carers was significantly different from the standard of care measurements (P = 0.008). In the hands of orthoptists. There was no significant difference between orthoptists using the iSight Test Pro and standard of care (P = 0.289), nor between orthoptist iSight Test Pro and parents/carer iSight Test Pro measurements (P = 0.108). Conclusion: This technique of unsupervised visual acuity measures for children is not comparable to clinical measures and is unlikely to be valuable to clinical decision making. Future work should focus on improving the accuracy of the test through better training, equipment/software or supervision/support.


  • Four cases of acute comitant esotropia associated with diffuse intrinsic pontine glioma in children

    by D Osborne, J Richardson-May, K Bush, M Evans, Sk West, K May, J Self

    Acute acquired concomitant esotropia (AACE) is usually a benign form of strabismus that infrequently is associated with intracranial pathology. Clinicians have noted an increase in its incidence an...


  • Open Access

    Impact of the COVID-19 pandemic on the research activities of UK ophthalmologists

    by H. D. J. Hogg, L. Low, J. E. Self, Royal College of Ophthalmologists’ Academic and Research Subcommittee, Louise Allen, Denize Atan, Rupert R. A. Bourne, Andrew D. Dick, Paul J. Foster, Richard P. Gale, et al.

    Background: The COVID-19 pandemic has impacted negatively on many areas of biomedical research and there is concern that academic recovery will take several years. This survey aimed to define the impact of the COVID-19 pandemic on UK ophthalmologists’ research activities and understand the implications for recovery. Methods: An online survey comprising multiple choice and free-text questions was designed, piloted and then distributed to Royal College of Ophthalmologists (RCOphth) members in January 2021. Respondent characteristics, research expectations and experiences through the pandemic were captured. Descriptive and comparative statistics were applied to quantitative data alongside content analysis of qualitative data. Results: In total, 148 respondents (3.7% of RCOphth membership) comprised 46 trainees (31.1%), 97 consultants (65.5%) and 5 SAS doctors (3.4%); 54 had clinical-academic roles (36.5%) and 65/94 (69.1%) ophthalmologists with fully clinical posts identified as research-active. Of 114 research-active respondents, 104 (91.2%) reported an impact on their research from COVID-19; negative impacts included loss of research time (n = 69), research delays (n = 96) and funding shortfalls (n = 63). Content analysis identified five common themes; type of research activity, clinical demands, institutional challenges, COVID-19 alignment and work-life balance. Conclusions: UK ophthalmology research has been adversely impacted by the pandemic. A substantial proportion of UK ophthalmologists are research active, but 20.4% of those surveyed felt that the pandemic had made research less attractive. Strategic steps must be taken to nurture UK ophthalmologists’ engagement with research, especially for those who currently do no research, if the profession is to align itself with the Government vision of ‘Research for All’.


  • Open Access

    Analysis of Fibroblast Growth Factor 14 (FGF14) structural variants reveals the genetic basis of the early onset nystagmus locus NYS4 and variable ataxia

    by Fabiola Ceroni, Daniel Osborne, Samuel Clokie, Dorine A. Bax, Emma J. Cassidy, Matt J. Dunn, Christopher M. Harris, Jay E. Self, Nicola K. Ragge

    Nystagmus (involuntary, rhythmical eye movements) can arise due to sensory eye defects, in association with neurological disorders or as an isolated condition. We identified a family with early onset nystagmus and additional neurological features carrying a partial duplication of FGF14, a gene associated with spinocerebellar ataxia type 27 (SCA27) and episodic ataxia. Detailed eye movement analysis revealed oculomotor anomalies strikingly similar to those reported in a previously described four-generation family with early onset nystagmus and linkage to a region on chromosome 13q31.3-q33.1 (NYS4). Since FGF14 lies within NYS4, we revisited the original pedigree using whole genome sequencing, identifying a 161 kb heterozygous deletion disrupting FGF14 and ITGBL1 in the affected individuals, suggesting an FGF14-related condition. Therefore, our study reveals the genetic variant underlying NYS4, expands the spectrum of pathogenic FGF14 variants, and highlights the importance of screening FGF14 in apparently isolated early onset nystagmus.